- Home
- SPRO vs CEPS Comparison
SPRO vs CEPS Comparison
Compare SPRO & CEPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRO | CEPS |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 148.8M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPRO | CEPS |
|---|---|---|
| Price | $2.70 | $10.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 408.3K | 44.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.65 | $10.07 |
| 52 Week High | $3.09 | $10.24 |
Technical Indicators
Market Signals| Indicator | SPRO | CEPS |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 56.42 |
| Support Level | $2.15 | $10.10 |
| Resistance Level | $2.70 | $10.22 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 85.53 | 42.41 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About CEPS Cantor Equity Partners VI Inc. Class A Ordinary Shares
Cantor Equity Partners VI Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.